Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.81 |
| ▸ | RET | P07949 | 4/20 | 0.48 |
| ▸ | ROS1 | P08922 | 4/20 | 0.48 |
| ▸ | FLT3 | P36888 | 4/20 | 0.48 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.48 |
| ▸ | VHL | P40337 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naquotinib SCHEMBL29355759 | 0.89 | EGFR (1.00) | EGFRRETROS1FLT3EML4 | |
| Naquotinib SCHEMBL19921009 | 0.89 | EGFR (1.00) | EGFRRETROS1FLT3EML4 | |
| Naquotinib SCHEMBL16196078 | 0.89 | EGFR (1.00) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL20149021 | 0.89 | EGFR (0.65) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL21367012 | 0.88 | EGFR (0.80) | EGFRRETROS1FLT3EML4 | |
| Naquotinib SCHEMBL18687011 | 0.87 | EGFR (0.95) | EGFRRETROS1FLT3EML4 | |
| Naquotinib SCHEMBL29409491 | 0.87 | EGFR (0.95) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16195821 | 0.86 | EGFR (1.00) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16207133 | 0.86 | EGFR (0.93) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16258223 | 0.85 | EGFR (0.72) | EGFRVHLJAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133325-A1 | STABILIZED PHARMACEUTICAL COMPOSITION | ASTELLAS PHARMA INC. (JP) | 2018-05-17 | — | — | US | disclosed |
| US-20170196859-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRAZINE CARBOXAMIDE COMPOUND AS ACTIVE INGREDIENT | ASTELLAS PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196859-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRAZINE CARBOXAMIDE COMPOUND AS ACTIVE INGREDIENT | BTK, JAK3, JAK2 | EGFR 286/4885RET 127/4885ROS1 242/4885 |
| US-20180133325-A1 | STABILIZED PHARMACEUTICAL COMPOSITION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WASHC5, ALB | EGFR 3365/4885RET 3733/4885ROS1 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.